Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

1

Tirzepatide is a dual GIP and GLP-1 receptor agonist that shows promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD).
2

In a study of 23 obese patients with MASLD, tirzepatide treatment for 3 months resulted in significant reductions in body weight and waist circumference.
3

Significant improvements were observed in metabolic parameters, including fasting glucose, HbA1c, insulin, and inflammatory markers after tirzepatide treatment.
4

Liver enzymes and the Fatty Liver Index (FLI) significantly decreased, indicating improvements in hepatic steatosis after tirzepatide therapy.
5

Δhs-CRP was identified as the only independent predictor of ΔFLI, explaining 29.8% of the variance in liver fat improvement.

Frontiers In Endocrinology

by Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri
July 6, 2026

1